|
| |
Overview
Financial Highlight
Headlines
Business Background Kotra Industries Bhd is an investment holding company. Along with its subsidiaries, the company is engaged in research and development, manufacturing and trading of pharmaceutical and healthcare products. Its product range includes nutraceutical and pharmaceutical products. It offers tablets, capsules, creams, and ointments under the brand name Appeton, Axcel, and Vaxcel. It operates in Malaysia.
  NPRA1985 UAE says Sinopharm vaccine has 86% efficacy against COVID-19 DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there. The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups. The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency. “The analysis shows no serious safety concerns,” it said. It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial. https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V 09/12/2020 3:20 PM NPRA1985 United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19 TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial. The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine. The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided. The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.” The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization. https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c 09/12/2020 10:25 PM NPRA1985 Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing. “The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people. “Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed. SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there. https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/ 10/12/2020 11:56 PM NPRA1985 Pfizer Vaccine Cleared in U.S., a Landmark in Covid-19 Fight Pfizer Inc. gained emergency U.S. authorization for its Covid-19 vaccine on Friday, completing an unprecedented scientific sprint that could eventually help bring an end to a pandemic that has killed nearly 300,000 Americans https://www.bloomberg.com/news/articles/2020-12-12/pfizer-covid-vaccine-wins-u-s-fda-emergency-use-authorization 12/12/2020 5:36 PM NPRA1985 Bahrain Approves China’s Sinopharm Covid-19 Vaccine Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine. “Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday. Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients. The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy. Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine. https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175 13/12/2020 5:31 PM NPRA1985 Govt to increase Covid-19 vaccine purchase to cover 60%-70% of M'sians — PM The government has plans to increase its purchase of the Covid-19 vaccine to cover the immunisation needs of about 60%-70% of Malaysians compared with 30% currently. Prime Minister Tan Sri Muhyiddin Yassin said this was because some nations had purchased doses exceeding their population. “As for Malaysia, we have already got 30%. I have instructed Health Minister Datuk Seri Dr Adham Baba along with [Science, Technology and Innovation Minister] Khairy Jamaluddin Abu Bakar to negotiate and increase it from 30% to 60% or 70%. https://www.theedgemarkets.com/article/govt-mulls-increasing-covid19-vaccine-purchase-30-6070-meet-msians-immunisation-needs-%E2%80%94-pm 13/12/2020 6:14 PM MF0001 KOTRA COME TO PAPA DROP TO PAPA 1.850 PLZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ :DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 25/03/2021 3:52 PM ValueMe Today traders buy tomorrow they sell.Only happens in KLSE.Just shows the level of confidence among investors and traders :D 01/09/2021 11:00 AM wallstreetrookie Under the radar pharmaceutical company. Similar to YSPSAH, Apex Healthcare 01/09/2021 12:10 PM wallstreetrookie This is the best company for M&A if this company is listed in other markets lol 01/09/2021 12:13 PM ValueMe Sell off before con yy starts promoting this stock. 30 percent in 1 week.Yummy Yummy. 01/09/2021 12:18 PM Primeinvestor superb results, no wonder limit up, how can it achieved such a good profit 01/09/2021 4:17 PM yang88 Yaloh, Revenue 43+m, profit 14m, profit margin 28%, incredible......how do they achieve?? 01/09/2021 6:22 PM wallstreetrookie @ipohwhitecoffee It is the only self-sustainable pharmaceutical company on Bursa. Very low risk compared to MGRC lolllll haha 13/12/2021 11:41 AM wallstreetrookie MGRC is high-risk bio tech firm. Kotra is boomer old fashioned Pharma bio tech company 13/12/2021 11:41 AM wallstreetrookie 2021 Q4 Revenue Breakdown 70.5% Malaysia 29.5% Other Countries APAC Excess Cash: 68.7 M P/FCF - 6.96 EV/EBITDA - 5.37 27/12/2021 12:01 PM treasurehunt Kotra liquidity is rather low. Gross Margin has surged more than double digit for the last 2 quarters. It's quite similar with Nova. But Nova fetchs at much higher multiple PER. 27/12/2021 12:11 PM treasurehunt Kotra has started its capex in last FY. Majority of the capex will be incurred in FY2022. AGM minutes 2020 For FY2021, the Group’s capital expenditure to upgrade manufacturing equipment, including cost of expansion of warehouse, is RM57 million. A major portion of the cost may be incurred mainly in FY2022. 27/12/2021 1:15 PM  | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
